Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Dekkers, Gillian ^a,b   Plomp, Rosina ^c   Koeleman, Carolien A M ^c   Visser, Remco ^a,b   Von Horsten, Hans H ^d,e   Sandig, Volker ^d   Rispens, Theo ^a,b   Wuhrer, Manfred ^c   Vidarsson, Gestur ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d PROBIOGEN AG   (Germany)

^e UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84996598787     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36964     Document Type: Article

References (56)

1. Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014).
2. Mimura, Y. et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol. Immunol. 37, 697-706 (2001).
3. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406, 267-273 (2000).
4. Subedi, G. P., Hanson, Q. M. & Barb, A. W. Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient Fcγ RIIIa binding. Structure 22, 1478-88 (2014).
5. Bowden, T. A. et al. Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J. Am. Chem. Soc. 134, 17554-17563 (2012).
6. Ahmed, A. A. et al. Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc Proteins. Journal of Molecular Biology 426, 3166-3179 (2014).
7. Subedi, G. P. & Barb, A. W. The Structural Role of Antibody N-Glycosylation in Receptor Interactions. Structure 23, 1573-83 (2015).
8. Ferrara, C. et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 108, 12669-12674 (2011).
9. Mizushima, T. et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes to Cells 16, 1071-1080 (2011).
10. Puccic Bakovic, M. et al. High-Throughput IgG Fc N-Glycosylation Profiling by Mass Spectrometry of Glycopeptides. J. Proteome Res. 12, 821-831 (2013).
11. Menni, C. et al. Glycosylation of immunoglobulin g: role of genetic and epigenetic influences. PLoS One 8, e82558 (2013).
12. Chen, G. et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J. Proteomics 75, 2824-2834 (2012).
13. Wang, J. et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol. Cell. Proteomics 10, M110.004655 (2011).
14. Kapur, R. et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 123, 471-480 (2014).
15. Kapur, R. et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br. J. Haematol. 166, 936-45 (2014).
16. Bondt, A. et al. Immunoglobulin G (IgG) Fab Glycosylation Analysis Using a New Mass Spectrometric High-throughput Profiling Method Reveals Pregnancy-associated Changes. Mol. Cell. Proteomics 13, 3029-3039 (2014).
17. Keusch, J., Lydyard, P. M. & Delves, P. J. The effect on IgG glycosylation of altering β 1,4-galactosyltransferase-1 activity in B cells. Glycobiology 8, 1215-1220 (1998).
18. Jones, M. B. et al. B-cell-independent sialylation of IgG. Proc. Natl. Acad. Sci. USA 113, 7207-12 (2016).
19. Jones, M. B., Nasirikenari, M., Lugade, A. A., Thanavala, Y. & Lau, J. T. Y. Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α 2,6-sialyltransferase 1 (ST6Gal-1) gene. J. Biol. Chem. 287, 15365-70 (2012).
20. Lee, M. M. et al. Platelets support extracellular sialylation by supplying the sugar donor substrate. J. Biol. Chem. 289, 8742-8748 (2014).
21. Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-40 (2002).
22. Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466-73 (2003).
23. Li, H. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24, 210-215 (2006).
24. Yamane-Ohnuki, N. & Satoh, M. Production of therapeutic antibodies with controlled fucosylation. mAbs 1, 230-236 (2009).
25. Jefferis, R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends in Pharmacological Sciences 30, 356-362 (2009).
26. Wuhrer, M. et al. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J. Proteome Res. 8, 450-456 (2009).
27. Sonneveld, M. E. et al. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. Br. J. Haematol. 174, 310-20 (2016).
28. Ackerman, M. E. et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123, 2183-92 (2013).
29. Hodoniczky, J., Yuan, Z. Z. & James, D. C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21, 1644-1652 (2005).
30. Umaña, P., Jean-Mairet, J., Moudry, R., Amstutz, H. & Bailey, J. E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176-180 (1999).
31. Ferrara, C. et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of golgi enzyme localization domain and co-expression of heterologous β 1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol. Bioeng. 93, 851-861 (2006).
32. Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475, 110-3 (2011).
33. Bondt, A. et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J. Proteome Res. 12, 4522-4531 (2013).
34. Dashivets, T. et al. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants. PLoS One 10, e0143520 (2015).
35. Houde, D., Peng, Y., Berkowitz, S. A. & Engen, J. R. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol. Cell. Proteomics 9, 1716-1728 (2010).
36. Pace, D. et al. Characterizing the effect of multiple Fc glycan attributes on the effector functions and Fcγ RIIIa receptor binding activity of an IgG1 antibody. Biotechnol. Prog. 1-12 doi: 10.1002/btpr.2300 (2016).
37. Fokkink, W. J. R. et al. Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G. PLoS One 10, e0139828 (2015).
38. von Horsten, H. H. et al. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. Glycobiology 20, 1607-1618 (2010).
39. Okeley, N. M. et al. Development of orally active inhibitors of protein and cellular fucosylation. Proc. Natl. Acad. Sci. USA 110, 5404-9 (2013).
40. Wang, J. et al. Glycomic signatures on serum IgGs for prediction of postvaccination response. Sci. Rep. 5, 7648 (2015).
41. Ruhaak, L. R. et al. The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer. EuPA open proteomics 6, 1-9 (2015).
42. Anthony, R. M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373-6 (2008).
43. Yang, Z. et al. Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat. Biotechnol. 33, 2014-2017 (2015).
44. Raymond, C. et al. Production of α 2,6-sialylated IgG1 in CHO cells. MAbs 7, 571-83 (2015).
45. Loch, N. et al. 2-Deoxy-2-fluoro-D-galactose protein N-glycosylation. FEBS Lett. 294, 217-220 (1991).
46. Barb, A. W. et al. NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 51, 4618-4626 (2012).
47. Barb, A. W., Brady, E. K. & Prestegard, J. H. Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. Biochemistry 48, 9705-7 (2009).
48. Bork, K., Horsttkorte, R. & Weidemann, W. Increasing the Sialylation of Therapeutic Glycoproteins: The Potential of the Sialic Acid Biosynthetic Pathway. J. Pharm. Sci. 98, 3499-3508 (2009).
49. Jones, M. B. et al. Characterization of the Cellular Uptake and Metabolic Conversion of Acetylated N-Acetylmannosamine (ManNAc) Analogues to Sialic Acids. Biotechnol. Bioeng. 85, 394-405 (2004).
50. Castilho, A. et al. Processing of complex N-glycans in IgG Fc-region is affected by core fucosylation. MAbs 7, 863-70 (2015).
51. Kruijsen, D. et al. Intranasal Administration of Antibody-Bound Respiratory Syncytial Virus Particles Efficiently Primes Virus-Specific Immune Responses in Mice. J. Virol. 87, 7550-7557 (2013).
52. Vidarsson, G., van de Winkel, J. G. J. & van Dijk, M. A. Multiplex screening for functionally rearranged immunoglobulin variable regions reveals expression of hybridoma-specific aberrant V-genes. J. Immunol. Methods 249, 245-52 (2001).
53. Vink, T., Oudshoorn-Dickmann, M., Roza, M., Reitsma, J. J. & de Jong, R. N. A simple, robust and highly efficient transient expression system for producing antibodies. Methods 65, 5-10 (2014).
54. Kapur, R. et al. Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. Transfusion 55, 553-562 (2015).
55. Chambers, M. C. et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol. 30, 918-20 (2012).
56. Plomp, R. et al. Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). Mol. Cell. Proteomics 14, 1373-1384 (2015).